NASDAQ: XBITXbiotech Inc Stock
$2.87-0.01 (-0.35%)
Updated Apr 29, 2025
XBIT Price
$2.87
Fair Value Price
$5.33
Market Cap
$87.50M
52 Week Low
$2.65
52 Week High
$9.45
P/E
-2.28x
P/B
0.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$38.53M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$31M
Beta
1.06
Next Earnings
May 8, 2025
Ex-Dividend
N/A
Next Dividend
N/A
XBIT Overview
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XBIT's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
XBIT
Ranked#396 of 462
Ranked#396 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important XBIT news, forecast changes, insider trades & much more!
XBIT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XBIT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XBIT ($2.87) is undervalued by 46.18% relative to our estimate of its Fair Value price of $5.33 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
XBIT ($2.87) is significantly undervalued by 46.18% relative to our estimate of its Fair Value price of $5.33 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
XBIT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XBIT due diligence checks available for Premium users.
Valuation
XBIT fair value
Fair Value of XBIT stock based on Discounted Cash Flow (DCF)
Price
$2.87
Fair Value
$5.33
Undervalued by
46.18%
XBIT ($2.87) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XBIT ($2.87) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XBIT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XBIT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.28x
Industry
-158.75x
Market
29.19x
XBIT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.48x
Industry
4.37x
XBIT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XBIT's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.5M
Profit Margin
0%
XBIT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$199.1M
Liabilities
$16.8M
Debt to equity
0.09
XBIT's short-term assets ($174.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XBIT's short-term assets ($174.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XBIT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
XBIT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.5M
Investing
-$84.0k
Financing
$283.0k
XBIT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XBIT vs Biotech Stocks
Xbiotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.